Literature DB >> 19487250

A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.

Shintaro Nakayama1, Ryo Atsumi, Hideo Takakusa, Yoshimasa Kobayashi, Atsushi Kurihara, Yoko Nagai, Daisuke Nakai, Osamu Okazaki.   

Abstract

The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry. Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose. We determined the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT. On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn. The covalent binding in each of the three test systems did not distinguish the safety categories clearly. However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear. An ordinal logistic regression analysis indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems. When two separation lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression analysis to create three zones, 30 of 37 tested drugs were located in zones corresponding to their respective classified safety categories. In conclusion, we established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487250     DOI: 10.1124/dmd.109.027797

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  26 in total

1.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

2.  The Proteome-Wide Potential for Reversible Covalency at Cysteine.

Authors:  Kristine Senkane; Ekaterina V Vinogradova; Radu M Suciu; Vincent M Crowley; Balyn W Zaro; J Michael Bradshaw; Ken A Brameld; Benjamin F Cravatt
Journal:  Angew Chem Int Ed Engl       Date:  2019-07-05       Impact factor: 15.336

Review 3.  Developing irreversible inhibitors of the protein kinase cysteinome.

Authors:  Qingsong Liu; Yogesh Sabnis; Zheng Zhao; Tinghu Zhang; Sara J Buhrlage; Lyn H Jones; Nathanael S Gray
Journal:  Chem Biol       Date:  2013-02-21

Review 4.  Contributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicology.

Authors:  Barbara L F Kaplan; Jinze Li; John J LaPres; Stephen B Pruett; Peer W F Karmaus
Journal:  Toxicol Sci       Date:  2015-06       Impact factor: 4.849

5.  Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment.

Authors:  Shakiru O Alapafuja; Michael S Malamas; Vidyanand Shukla; Alexander Zvonok; Sally Miller; Laura Daily; Girija Rajarshi; Christina Yume Miyabe; Honrao Chandrashekhar; JodiAnne Wood; Sergiy Tyukhtenko; Alex Straiker; Alexandros Makriyannis
Journal:  Bioorg Med Chem       Date:  2018-11-03       Impact factor: 3.641

6.  Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Authors:  Nagsen Gautam; Rhishikesh Thakare; Sandeep Rana; Amarnath Natarajan; Yazen Alnouti
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

7.  Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification.

Authors:  Rosa Chan; Leslie Z Benet
Journal:  Toxicol Res (Camb)       Date:  2018-04-18       Impact factor: 3.524

8.  Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes.

Authors:  Yakov M Koen; Diganta Sarma; Todd D Williams; Nadezhda A Galeva; R Scott Obach; Robert P Hanzlik
Journal:  Chem Res Toxicol       Date:  2012-04-10       Impact factor: 3.739

9.  Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes.

Authors:  Jennifer L Goldman; Yakov M Koen; Steven A Rogers; Kelin Li; James S Leeder; Robert P Hanzlik
Journal:  Drug Metab Dispos       Date:  2016-07-25       Impact factor: 3.922

Review 10.  Mechanism of isoniazid-induced hepatotoxicity: then and now.

Authors:  Imir Metushi; Jack Uetrecht; Elizabeth Phillips
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.